[Comparison of different drugs on the treatment of benign prostate hyperplasia].
OBJECTIVE
To compare the differences of the efficacy and different therapeutic drugs on the treatment of benign prostatic hyperplasia (BPH) in order to ensure the optimal indication for different BPH patients.


METHODS
A randomized, parallel-controlled, multicenter clinical trial was conducted. From September 2002 to December 2003 906 BPH patients were enrolled into 7 therapeutic groups, including selective-adrenoceptor antagonist (terazosin, doxazosin tamsulosin and naftopidil), 5 alpha-reductase inhibitor (finasteride and epristeride) and natural product (cernilton). International Prostate Symptom Score (IPSS) and Quality of Life (QOL), uroflowmetry, total prostatic volume (TPV) and transitional zone volume and residual urine were used as efficacy criteria.


RESULTS
According to the baseline, the IPSS and Qmax were significantly correlated to the prostatic volume and transitional zone volume (P < 0.01). At average follow-up of 6 months, significant improvements in IPSS, QOL, Qmax and residual urine volume were observed in each therapeutic group, and no difference in IPSS improvement was found among the groups. Prostatic volume and transitional zone volume were significant decreased in 5alpha-reductase inhibitor groups (P < 0.05). In patients with baseline TPV greater than 35.5 cm3, the improvement of Qmax was more significant than that in patients with TPV less than 35.5 cm3 in finasteride group (P < 0.01) (5.7 ml/s and 2.2 ml/s respectively), and more significant symptomatic improvements were also found in cernilton, doxazosin and naftopidil group. In each group, the improvement of symptom were more significant in patients with IPSS higher than 20 points (P < 0.01).


CONCLUSIONS
Each drug observed in this study can improve the subjective and objective symptoms significantly for BPH patients, especially for patients with higher IPSS baseline. When using 5alpha-reductase inhibitor, prostatic volume can be decreased significantly and more obviously subjective and objective improvement can be found in the patients with TPV greater than 35.5 cm3.
Li
Ning-chen
NC
Department of Urology, Peking University First Hospital, Institute of Urology, Beijing 100034, China. ningchenli@126.com
Wu
Shi-liang
SL
Jin
Jie
J
Qiu
Shao-peng
SP
Kong
Chui-ze
CZ
Song
Yong-sheng
YS
Ye
Zhang-qun
ZQ
Sun
Guang
G
Sun
Ying-hao
YH
Sun
Yu-cheng
YC
Wang
Xiao-feng
XF
Na
Yan-qun
YQ
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000730:Androstadienes / Q000627:therapeutic use; D004311:Double-Blind Method; D017292:Doxazosin / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D010936:Plant Extracts / Q000627:therapeutic use; D011224:Prazosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011467:Prostate / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011788:Quality of Life; D012434:Secale; D013449:Sulfonamides / Q000627:therapeutic use; D000077409:Tamsulosin; D016896:Treatment Outcome
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D000730:Androstadienes; D004791:Enzyme Inhibitors; D009281:Naphthalenes; D010879:Piperazines; D010936:Plant Extracts; D013449:Sulfonamides; C072547:epristeride; D018120:Finasteride; C010070:cernilton; C041226:Terazosin; D000077409:Tamsulosin; D017292:Doxazosin; C064357:naftopidil; D011224:Prazosin